Department of Breast and Endocrinology Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan;
Anticancer Res. 2023 May;43(5):2145-2154. doi: 10.21873/anticanres.16376.
BACKGROUND/AIM: This study aimed to examine the clinical significance of the protein expression of the cancer stem cell (CSC) markers ALDH1A1, CD133, CD44, and MSI-1 in primary and metastatic tissues of patients with breast cancer (BC).
ALDH1A1, CD133, CD44, and MSI-1 protein expression in pairs of primary and metastatic tissues of 55 patients with BC with metastases treated at Kanagawa Cancer Center between January 1970 and December 2016 were evaluated using immunohistochemical assay and their association with clinicopathological factors and survival was examined.
There were no significant differences in CSC marker expression rates between primary and metastatic tissues for any CSC markers. Regarding the relationship between CSC marker expression in primary tissues and survival, patients with high CD133 expression had significantly lower recurrence-free survival (DFS) and overall survival. On multivariate analysis, they were also a poor independent predictor of DFS (hazard ratio=4.993, 95%CI=2.189-11.394, p=0.0001). In contrast, there was no significant association between the expression of any CSC marker in metastatic tissues and survival.
CD133 expression in the primary BC tissue may be a useful risk factor for recurrence in patients with BC.
背景/目的：本研究旨在探讨癌症干细胞（CSC）标志物 ALDH1A1、CD133、CD44 和 MSI-1 在原发性和转移性乳腺癌（BC）患者组织中的蛋白表达的临床意义。
采用免疫组织化学法检测 55 例 1970 年 1 月至 2016 年 12 月在神奈川癌症中心治疗的有转移的 BC 患者的原发性和转移性组织中 ALDH1A1、CD133、CD44 和 MSI-1 蛋白的表达，并分析其与临床病理因素和生存的关系。
任何 CSC 标志物在原发性和转移性组织中的表达率均无显著差异。关于原发性组织中 CSC 标志物表达与生存的关系，高 CD133 表达的患者复发无病生存（DFS）和总生存显著降低。多因素分析显示，CD133 表达也是 DFS 的不良独立预测因子（危险比=4.993，95%CI=2.189-11.394，p=0.0001）。相比之下，转移性组织中任何 CSC 标志物的表达与生存均无显著相关性。
原发性 BC 组织中 CD133 的表达可能是 BC 患者复发的一个有用的危险因素。
